Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 13/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | APEX1 | P27695 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.35 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29447829 | 0.89 | PDK2 (0.41) | PDK2POLBAPEX1HTTTDP1 | |
| SCHEMBL10233458 | 0.89 | PDK2 (0.41) | PDK2POLBAPEX1HTTTDP1 | |
| SCHEMBL20411189 | 0.87 | POLB (0.42) | PDK2POLBAPEX1HTTTDP1 | |
| SCHEMBL25784653 | 0.85 | PDK2 (0.39) | PDK2POLBAPEX1HTTTDP1 | |
| SCHEMBL24469748 | 0.85 | PDK2 (0.40) | PDK2POLBAPEX1HTTTDP1 | |
| SCHEMBL22648010 | 0.85 | THRB (0.48) | PDK2MAPTL3MBTL1LMNATP53 | |
| SCHEMBL22648808 | 0.85 | THRB (0.44) | PDK2MAPTL3MBTL1LMNATP53 | |
| SCHEMBL25784469 | 0.85 | L3MBTL1 (0.39) | PDK2POLBAPEX1HTTTDP1 | |
| SCHEMBL25784463 | 0.83 | PDK2 (0.37) | PDK2POLBAPEX1HTTTDP1 | |
| SCHEMBL17880797 | 0.81 | CYP3A4 (0.44) | PDK2POLBAPEX1HTTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11718580-B2 | Fluorene derivatized monomers and polymers for volume Bragg gratings | META PLATFORMS TECHNOLOGIES, LLC (US) | 2023-08-08 | — | — | US | disclosed |
| US-20200354311-A1 | FLUORENE DERIVATIZED MONOMERS AND POLYMERS FOR VOLUME BRAGG GRATINGS | META PLATFORMS TECHNOLOGIES, LLC | 2020-11-12 | — | — | US | disclosed |
| WO-2020227264-A1 | FLUORENE DERIVATIZED MONOMERS AND POLYMERS FOR VOLUME BRAGG GRATINGS | FACEBOOK TECHNOLOGIES, LLC (US) | 2020-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200354311-A1 | FLUORENE DERIVATIZED MONOMERS AND POLYMERS FOR VOLUME BRAGG GRATINGS | RHOA, PARG, LSG1 | PDK2 4171/4885POLB 3223/4885APEX1 3211/4885 |
| US-11718580-B2 | Fluorene derivatized monomers and polymers for volume Bragg gratings | RHOA, PARG, LSG1 | PDK2 4171/4885POLB 3223/4885APEX1 3211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.